Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
VanEck Pharmaceutical ETF (PPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/04/2025: PPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type ETF | Historic Profit 12.91% | Avg. Invested days 62 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  3.0 |
| Profits based on simulation | Last Close 02/04/2025 |
Key Highlights
Volume (30-day avg) 245397 | Beta 0.57 | 52 Weeks Range 83.56 - 98.62 | Updated Date 04/2/2025 |
52 Weeks Range 83.56 - 98.62 | Updated Date 04/2/2025 |
Upturn AI SWOT
VanEck Pharmaceutical ETF
ETF Overview
Overview
The VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Pharmaceuticals Index, which tracks companies involved in pharmaceuticals.
Reputation and Reliability
VanEck is a well-established ETF provider with a long track record.
Management Expertise
VanEck has extensive experience in managing sector-specific ETFs.
Investment Objective
Goal
Seeks to replicate the price and yield performance of the Indxx Global Pharmaceuticals Index.
Investment Approach and Strategy
Strategy: Tracks the Indxx Global Pharmaceuticals Index.
Composition Primarily holds stocks of pharmaceutical companies.
Market Position
Market Share: Data unavailable at the moment
Total Net Assets (AUM): 45876730
Competitors
Key Competitors
- XBI
- IBB
- FXH
Competitive Landscape
The pharmaceutical ETF market is moderately competitive with bigger players dominating. PPH faces competition from broader healthcare ETFs and other pharmaceutical-specific funds. Advantages of PPH might include a specific indexing methodology or lower expense ratio (check current rates), while disadvantages may include lower AUM and trading volume than larger competitors like IBB and XBI.
Financial Performance
Historical Performance: Historical performance data is available on financial websites (Yahoo Finance, etc.). Please see disclaimer
Benchmark Comparison: Comparison data is available on financial websites (Yahoo Finance, etc.). Please see disclaimer
Expense Ratio: 0.35
Liquidity
Average Trading Volume
The average trading volume fluctuates, but based on past data is often low, indicating lower liquidity than broader ETFs.
Bid-Ask Spread
The bid-ask spread can vary depending on market conditions and time of day but is generally wider than more liquid ETFs because of low volume.
Market Dynamics
Market Environment Factors
Economic conditions, healthcare policies, regulatory changes, and pharmaceutical industry growth prospects impact PPH.
Growth Trajectory
The growth trajectory depends on the performance of the pharmaceutical sector and any strategic shifts in PPH's holdings.
Moat and Competitive Advantages
Competitive Edge
PPH's advantage lies in its focused exposure to pharmaceutical companies and this is achieved by tracking the Indxx Global Pharmaceuticals Index. This niche focus can appeal to investors specifically bullish on the pharmaceutical sector. However, it lacks any unique differentiation in investment strategy or superior management compared to other large competitors. Its lower liquidity and AUM also represent some disadvantages for the investors.
Risk Analysis
Volatility
PPH's volatility is correlated to the performance of the pharmaceutical industry and is subject to regulatory and patent-related risks.
Market Risk
Risks include regulatory changes, patent expirations, clinical trial failures, and overall market sentiment towards the pharmaceutical sector.
Investor Profile
Ideal Investor Profile
Investors seeking targeted exposure to the pharmaceutical industry and who are bullish on the sector's growth prospects.
Market Risk
Suitable for long-term investors with a specific interest in the pharmaceutical industry and are aware of industry-specific risks. It may not be suitable for active traders due to lower liquidity.
Summary
VanEck Pharmaceutical ETF (PPH) provides targeted exposure to the pharmaceutical industry by tracking the Indxx Global Pharmaceuticals Index. While it offers a focused investment approach, its lower AUM and trading volume may pose liquidity challenges. The ETF's performance is heavily influenced by the pharmaceutical sector's performance, making it suitable for investors with a specific bullish outlook and a long-term investment horizon. Investors should be aware of industry-specific risks such as regulatory changes and patent expirations. Compared to its competitors, its competitive advantages are not very strong, which limits its ability to take the market share.
Similar Companies
- XBI
- IBB
- FXH
- ITA
Sources and Disclaimers
Data Sources:
- Vaneck.com
- Yahoo Finance
- etfdb.com
- Google Finance
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. ETF data and market conditions can change rapidly. Consult a financial advisor before making any investment decisions. Market share is an approximation based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VanEck Pharmaceutical ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.